Drug intelligence / Profile preview

rilparencel

Development stage: Phase 3
Lead developer: ProKidney
Modality: Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intra-renal

Overview

Rilparencel (also known as REACT) is a first-in-class, autologous cellular therapy developed by ProKidney for the treatment of advanced chronic kidney disease (CKD), particularly in patients with diabetic nephropathy. The therapy is produced by isolating a patient's own kidney cells from a biopsy, expanding specific renal epithelial cells in a laboratory, and formulating them into a personalized product for re-injection. Administered via a percutaneous intra-renal injection, rilparencel is designed to stabilize or improve kidney function by reducing inflammation, fibrosis, and the progressive scarring that leads to kidney failure. It has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is currently being evaluated in Phase 3 clinical trials.

Brand names: REACT
Other names: Renal Autologous Cell Therapy

Beyond the preview

Go deeper on rilparencel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rilparencel.

Explore the full profile